Methylnaltrexone potentiates the antiangiogenic effects of the mTOR inhibitor, temsirolimus No significant financial relationships to disclose. This is an ASCO Meeting Abstract from the 2009 ASCO ...
Quality of life (QOL) as a predictor of clinical outcome in patients (pts) with head and neck cancer (HNC). This is an ASCO Meeting Abstract from the 2015 ASCO Annual Meeting I. This abstract does not ...
Cancer-related fatigue (CRF) is a debilitating yet all-too-common condition, which can severely affect quality of life for patients undergoing treatment. For those struggling with CRF, there have been ...
Researchers have developed a new method to grow T cells that have greater longevity and can more efficiently destroy cancer cells in mouse models of melanoma compared to those grown in traditional ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results